© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Expert physicians discuss the rationale behind the clinical use of JAK inhibitors in acute GvHD (graft-versus-host disease), and provide an overview of recent clinical trial data for this treatment approach.
December 23rd 2020
A discussion on the role on Janus kinase signaling in the pathogenesis of acute and chronic graft-vs-host disease (GVHD).
Expert physicians discuss the role and efficacy of JAK inhibitors in steroid-refractory graft-vs-host disease (GVHD).
Key opinion leaders discuss treatment goals for frontline therapy in patients with acute graft-vs-host disease.
A discussion on decision factors for switching to and deciding upon a second-line therapy, and an overview of the phase 3 REACH2 study with ruxolitinib for glucocorticoid-refractory acute graft-vs-host disease (GVHD).
Key opinion leaders provide community oncologists with advice for implementing the REACH2 regimen to manage patients with acute graft-vs-host disease (GVHD).
Expert physicians consider how ongoing developments will impact the treatment paradigm of graft-vs-host disease.
A discussion on upcoming clinical trial data presentations featured at the American Society of Hematology (ASH) 2020 Annual Meeting.
Key opinion leaders close the discussion by providing insight into their respective protocols for acute graft-vs-host (GVHD) disease prophylaxis.